Top Markets
#1 PulseChain PulseChain +45.01%
#2 SkyAI SkyAI +12.67%
#3 Meteora Meteora +11.24%
#4 Glidr Glidr +9.27%
#5 OPENLOOT OPENLOOT +8.94%
#6 Unit Pump Unit Pump +8.52%
#7 Pump.fun Pump.fun +8.52%
#8 Lorenzo Wrapped Bitcoin Lorenzo Wrapped Bitcoin +7.55%
#9 eCash eCash +7.18%
#10 Cash Cat Cash Cat +7.15%
Coin of the day
PulseChain PulseChain
Ayarlar
Dil
TüRKçE
Para birimi
USD
Tema
Marinus Pharmaceuticals, Inc. Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

MRNS
Hisse Senetlerindeki Sıralama #28041
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated... Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD). This medication is prescribed for both adult and pediatric patient populations, suitable for use in acute and chronic care settings, and can be administered either in-patient or by the patient themselves. ZTALMY exerts its effect by targeting synaptic and extrasynaptic GABAA receptors, a mechanism that also suggests potential anticonvulsant, antidepressant, and anxiolytic benefits. Beyond ZTALMY, Marinus is actively progressing ganaxolone through development, an investigational therapy aimed at various genetic epileptic conditions such as PCDH19-related epilepsy, tuberous sclerosis complex, and Lennox-Gastaut Syndrome, with additional exploration for depressive disorders. The company maintains strategic alliances, including licensing agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc., as well as a collaborative partnership with Orion Corporation. Marinus Pharmaceuticals was established in 2003 and operates from its corporate headquarters in Radnor, Pennsylvania.
Hisse Fiyatı
$0.55
Son senkronizasyon: 2025-02-11
Piyasa Değeri
$28.90M
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Marinus Pharmaceuticals, Inc. (MRNS)

Kategori

Healthcare
Marinus Pharmaceuticals, Inc. (MRNS) için Faaliyet Marjı
August 2026 itibarıyla Faaliyet Marjı TTM: -424.30%
Marinus Pharmaceuticals, Inc. şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) -424.30%'dir. 2022 yılı sonunda şirketin faaliyet marjı -442.69% idi.
Marinus Pharmaceuticals, Inc. için 2012 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
Yıl Faaliyet Marjı Değiştir
2026 (TTM) -424.30% 0.00%
2023 -424.30% -4.15%
2022 -442.69% -29.92%
2021 -631.68% -84.03%
2020 -3,954.42% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% -100.00%
2012 -1,430.66% 0.00%
Benzer şirketler veya rakipler için Faaliyet Marjı
Şirket Faaliyet Marjı Faaliyet Marjı Farkı Ülke
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -100.09%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -99.65%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -100.07%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.06%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.